Therapeutic options for advanced thyroid cancer

Apoorva Jayarangaiah¹, Gurinder Sidhu², Jordonna Brown², Odeth Barrett-Campbell², Gul Bahtiyar³, Irini Youssef³, Shalini Arora³, Samara Skwiersky², Samy I McFarlane²,∗

¹Department of Internal Medicine, Jacobi Medical Center, Albert Einstein School of Medicine, New York, USA

²Divisions of Endocrinology and Hematology-Oncology, Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, USA

³Department of Surgery, Kings County Hospital Center, Brooklyn, New York, USA

Abstract

Thyroid cancer can be largely classified as well-differentiated, poorly differentiated, medullary and anaplastic. Differentiated thyroid cancer (DTC) includes follicular and papillary subtypes, with the incidence of papillary thyroid cancer (PTC) on the rise. The mainstay of treatment for DTC includes a combination of surgery, radioactive iodine (RAI) and levothyroxine suppression. DTC portends a favorable prognosis, even in the presence of distant metastases, with a 50% rate of 5-year survival largely due to tumor cell’s sensitivity to RAI therapy influencing disease outcome. In radioactive iodine refractory differentiated thyroid cancer (RAI-refractory DTC) there is a lower survival rate prompting the use of other therapeutic options available. RAI refractoriness is more common in older patients (age >40), large metastases and lesions that are fluorodeoxyglucose (FDG) avid on position emission tomography (PET). Over the past decade, Identification of genetic mutations in the signaling pathway involved in thyroid tumorigenesis has led to the approval of tyrosine kinase inhibitors (TKIs); Sorafenib and Lenvatinib in RAI-refractory DTC. Similarly, metastatic medullary thyroid cancer (MTC) implies an unfavorable 10-year survival rate of only 20% as the principal treatment options focuses on loco regional control via surgical and/or non-surgical options. The approval of TKIs such as Cabozantinib and Vandetanib has introduced an encouraging, novel, systemic therapeutic option for metastatic MTC. Lastly, anaplastic thyroid cancer (ATC) carries the worst prognosis with high recurrence rates. Treatment includes surgery, chemotherapy and external beam radiation. The FDA recently approved Dabrafenib plus trametinib for BRAF V600E mutated ATC.

Considering the modality of chemotherapy and the expanding field of targeted therapies, the role of the oncologist and interaction with endocrinologist in the management of thyroid cancer needs further clarification aiming at collaborative management plans more than ever. This review summarizes the key phase III trials that led to the approval of TKIs in the treatment of DTC and

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Corresponding author: Samy I McFarlane, MD, MPH, MBA, FACP, Distinguished Teaching Professor and Associate Dean, Department of Medicine, Division of Endocrinology, Internal Medicine Residency Program Director, State University of New York-Downstate Medical Center, 450 Clarkson Avenue, Box 50, Brooklyn, New York, 11203, USA, Tel: 718-270-3711; Fax: 718-270-6358; Samy.mcfarlane@downstate.edu.
metastatic MTC. Additionally, the review aims to clarify the patient selection criteria for initiation of TKIs and examine the implications, considerations and adverse effects prior to utilizing targeted therapy. Clinical trials are ongoing with promising results and may contribute to the addition of several targeted molecules and immune check point inhibitors to the therapeutic armamentarium for RAI-refractory DTC, medullary and anaplastic thyroid cancer.

Introduction

Thyroid cancer is the most common endocrine malignancy with its incidence on the rise. Differentiated thyroid cancer comprises of follicular and papillary subtypes and accounts for 95% of the thyroid cancer [1]. Medullary and Anaplastic thyroid cancers make up 4% of the thyroid cancers [1]. DTC is typically managed by endocrinologists as it responds favorably to the conventional treatment which includes surgical resection, RAI, TSH suppression therapy with monitoring. There is no role for RAI therapy in MTC and ATC [1]. Surgery and other means of loco regional control are therapeutic options in MTC [2]. The role of chemotherapy is limited in the management of all thyroid cancers, with the most significant role being in ATC.

This report explores the circumstances in which differentiated thyroid cancer (DTC) management deviates from the standard therapy, specifically describing the indications for targeted therapy and updates within the field. In addition, we aim to further describe the role of the oncologist in the management of medullary as well as anaplastic thyroid cancer.

Differentiated thyroid cancer

Differentiated thyroid cancers constitute about 95% of thyroid cancers [1]. This constitutes cancers arising from the thyroid follicular epithelial cells; namely papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). PTC accounts for 85% of diagnosed cases of DTC with 12% being FTC [2]. Both PTC and FTC generally exhibit a desirable response to initial therapy, therefore DTC is considered to have a good prognosis. A robust initial approach to a patient with DTC is aimed at improving overall and disease specific outcomes, reducing the risk of persistent or recurrent disease and reducing morbidity [1]. The initial management of DTC emphasizes on complete surgical resection of primary tumor and loco-regional nodal metastases [3]. The extent of surgical resection and preoperative staging is beyond the scope of this review. While surgical resection remains the primary management, RAI and suppressive thyroid hormone remains integral to the postoperative management of DTC. RAI is the mainstay therapy for all patients with DTC. It is used to ablate residual normal thyroid tissue (remnant ablation), adjuvant therapy or therapy for persistent disease [1,4,5].

The role of chemotherapy in DTC

Doxorubicin was FDA approved in 1974 for the treatment of thyroid cancer. Chemotherapy regimens with doxorubicin have shown 31%–45% partial response [6–8]. The proposed utility of neo-adjuvant chemotherapy in inoperable primary thyroid cancer and loco-regional control in DTC were presented in a non-randomized, retrospective trial by Basic [9,10]. The results showed comparable response rates with a decrease in tumor size in both FTC and
PTC (45% and 44% respectively) [9,10]. Dang et al., reviewed the effects of neoadjuvant chemotherapy in reducing morbid or complicated surgical resection [11]. Despite a few trials which showed beneficial results in locally invasive disease, the data had several limitations and neoadjuvant chemotherapy is not currently recommended [11]. Doxorubicin with cisplatin did not result in additional overall response compared to doxorubicin alone [12,13]. Several other combination chemotherapy regimens have not yielded any encouraging results either [14–16]. Per American Thyroid Association (ATA) guidelines, systemic adjuvant therapy referencing systemic chemotherapy or targeted inhibitor therapies are not routinely indicated in DTC [1]. Furthermore, the poor response rates, short duration of response and toxic effects of chemotherapy deems it inadvisable in patients with DTC [17].

**RAI- refractory DTC**

DTC typically portends a favorable prognosis with a 10-year survival rate greater than 90% with a 10%–20% risk of recurrence [18]. In the event of recurrence, standard treatment is typically reconsidered. Even in the setting of metastatic DTC, 40% of patients remain disease free at 5 years [18,19]; this is largely attributed to RAI avidity in the majority of DTCs. The most common sites of distant metastases are lung, bone, brain, liver and skin [18]. There is a subset of DTC which shows an inherent resistance to RAI therapy, termed radioiodine (RAI)-refractory differentiated thyroid cancer. The 5-year disease specific survival rate of RAI-refractory DTC is 66% [20] with the 10-year survival rate being only 10% [21].

**There are four classes of RAI-resistance as defined in the 2015 ATA guidelines [18], these include**

i. The malignant/metastatic tissue does not ever concentrate RAI (no uptake outside the thyroid bed at the first therapeutic whole-body scan),

ii. The tumor tissue loses the ability to concentrate RAI after previous evidence of RAI-avid disease (in the absence of stable iodine contamination)

iii. RAI is concentrated in some lesions but not in others

iv. Metastatic disease progresses despite significant concentration of RAI. The development of RAI-resistance which occurs later during the disease, specifically following initial RAI treatment is particularly associated in patient with multiple, large metastases [22]. The theory exists that the initial RAI therapy leads to the selected survival of poorly differentiated cells with an inherent RAI resistance. The likelihood of progression of these lesions remain higher specifically when 18FDG uptake is seen [22,23].

A lack of a defined consensus makes identification of RAI refractory DTC challenging. A more in-depth definition of RAI refractory DTC which considers variables such as progression based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria, appropriate imaging modality and tumor markers is needed [24,25]. For now, a carefully weighed decision to determine the utility of RAI should be made in those patients who demonstrate the latter criteria. RAI should be continued to be used only when a clear benefit is shown since ongoing RAI therapy does carry a risk of secondary malignancies [26,27].
The role of targeted therapy in differentiated cancer

In recent years, the identification of genetic alterations in thyroid carcinogenesis has shifted the focus on exploring the role of targeted therapies in thyroid cancer [28]. Mutations in the intracellular signaling pathways involving RAS, BRAF and PI3K/Akt play a key role in thyroid tumor cell growth and survival [29–31]. Additionally, vascular endothelial growth factor (VEGF) and its receptors (VEGFR) are also implicated in aggressive thyroid carcinoma [32,33]. Studies have shown RET/PTC and BRAFV600E mutations to commonly occur in PTC while RAS point mutations are largely seen in FTC and poorly differentiated thyroid carcinoma [33,34]. Therapeutic options in RAI-refractory DTC has expanded with the advent of tyrosine kinase inhibitors.

Randomized control trials

Several phase II trials with VEGF inhibitors have showed promising results in progression free survival [35–38].

Two randomized placebo-controlled phase III clinical trials (DECISION, SELECT) have led to US Food and Drug Administration (FDA) approval of TKIs for treatment of progressive RAI-refractory DTC [39–43]. In the DECISION trial, Sorafenib, an MKI which has an inhibitory effect on VEGF-1, −2 and −3, platelet-derived growth factor receptor (PDGFR), BRAF and RET demonstrated a benefit in median progression free survival (PFS) over the placebo group (10.8 vs 5.8 months) [39]. The SELECT trial reported significantly longer median PFS with Lenvatinib vs placebo (18.3 versus 3.6 months) [40]. These results were demonstrated across all subgroups, including those previously treated with a tyrosine kinase inhibitor [41]. Despite encouraging results demonstrating superior PFS in these key trials, there is no conclusive data regarding overall survival due to lack of data points at the end of the trial and crossover which occurred during the trial. There were also increased reports of adverse effects in the TKI group.

Adverse events

The significant side effects associated with VEGFR TKIs ranging from minor, temporary side effects to potentially life threatening adverse events govern in part the decision to pursue treatment with these agents [44]. In the SELECT trial, 75% of the patients treated with Lenvatinib experienced grade 3 or higher side effects [40,45]. The most common adverse effects reported include hypertension (necessitating initiation of an antihypertensive), diarrhea, anorexia. Side effects should be promptly recognized and managed either by implementing appropriate treatment, dose reduction or treatment cessation. TKI therapy is a long-term therapy and treatment duration is determined based on treatment response and side effects. TKI therapy is discouraged in patients with preexisting co-comorbidities due to the increased risk of adverse events [45,46] (Table 1).

Candidacy of treatment

Prior to initiation of a kinase inhibitor, the patient and the physician must make a well-informed decision, with careful consideration of the risks including adverse events and lower quality of life weighed against the individualized benefits obtained from these therapies [47].
Albeit, there is still a need for a more robust, evidence-based approach to determine appropriate time for referral to an oncologist and the ideal time to initiate a TKI.

When a patient is initially diagnosed with metastatic RAI refractory DTC, if the patient is asymptomatic, or the spread disease remains stable or indolent without a risk for encroachment on vital structures, close monitoring along with TSH suppressive therapy is advised [47,48].

In patients with single or oligometastatic disease who are symptomatic and carry a high risk for complications, directed therapy aimed at local control such as surgery, stereotactic radiation, External beam radiation therapy (EBRT), thermal ablation (radiofrequency ablation and cryoablation) and chemoembolization should be considered prior to initiation of systemic therapy (such as a TKI) [49–52]. These treatment modalities aim to achieve local disease control and delay the need for systemic therapy.

The ATA currently recommends “Kinase inhibitor therapy should be considered in RAI refractory DTC patients with metastatic, rapidly progressive, symptomatic, and/or imminently threatening disease not otherwise amenable to local control using other approaches [1].”

In conclusion, initiation of a TKI should occur in consultation with an oncologist and should be tailored to each patient to achieve stable disease, minimize progression and aid with symptom management. It is indicated based on tumor burden, tumor progression utilizing the RECIST criteria and imminent threat to vital structures [53]. For patients with slow tumor growth (less than 20%) increase in a year, observation may be indicated. Sabra et al., suggest a potential role for volume doubling time (VDT) to aid in determining the decision to initiate targeted therapy [54].

Additionally, while there has been improvement of PFS, there is no evidence on OS with TKIs. Stable disease appears to be the most likely outcome. Furthermore, the data from the cross over trials can be best interpreted as no difference in outcomes when TKI therapy was delayed [55].

With continued use, secondary resistance to a TKI is a well know phenomenon, often necessitating salvage therapy [56,57]. Failure of therapy with an initial TKI justifies consideration of a second TKI if not limited by side effects. The choice of TKIs is currently only guided by data provided by randomized control trials or in the context of clinical trials. A retrospective review by Dadu et al., demonstrated longer median overall survival (OS) salvage therapy compared with sorafenib alone (58 vs 28 months, P = .013) in patients with advanced RAI refractory DTC [58]. Based on these trials, it can be recommended that if disease progression or intolerance to sorafenib is experienced, salvage therapy with an alternative TKI is warranted [58]. Another large retrospective trial reported stable disease in DTC patients treated with a second-line therapy but with similar median PFS [59]. Interestingly, another retrospective study at MD Anderson, while it corroborated the clinical benefit of first-line and second-line TKIs in metastatic RAI refractory DTC, it additionally identified differential responses at various metastatic sites. The study revealed that
regression of lung metastases was most common, with the least response and even progression of disease seen in previously non-irradiated bony metastases [60].

**Future therapies in DTC**

Given the poor outcomes in RAI-refractory thyroid cancer, several clinical trials are ongoing to study the efficacy of targeting the various tumor mutations associated with DTC including BRAF, ALK, mTOR or PAX8/PPARy rearrangements [61]. Given that RAI therapy has such a crucial role in the treatment of DTC, a promising field in RAI refractory DTC research explores iodine resensitization therapies. RAI refractoriness occurs due to the down regulation of the sodium-iodide symporter gene [62]. A phase II trial with a MEK inhibitor, selumetinib demonstrated increased iodide uptake in 12 out of 20 patients, specifically in patients with RAS mutations [63]. A phase II trial with Dabrafenib (BRAF inhibitor) showed increased RAI uptake in 60% of the patients [64]. Other areas of interest include check point inhibitors such as pembrolizumab and combination therapies with other MKIs to counteract the escape mechanism [65].

**Medullary thyroid cancer (MTC)**

Medullary thyroid cancer (MTC) accounts for 3%–5% of the thyroid cancer diagnosis of which 75% are sporadic and 25% are familial, typically MEN2A and MEN2B [66]. The systemic approach to the management of MTC hinges on identifying the stage of MTC. Total thyroidectomy with compartment-oriented lymph node dissection is the initial treatment in localized MTC [66,67]. There is no role for radioactive iodine in MTC [66].

The decision to treat metastatic MTC is pursued to improve quality and quantity of life. In advanced progressive MTC, further spread endangers vital structures which mandates treatment for survival. Pain and hormonal manifestations impose significant burdens on quality of life, making it imperative to pursue control of disease either by loco regional control or systemic therapies [68]. Measures such as tumor burden, rate of progression on sequential imaging as defined by the RECIST criteria and tumor marker doubling times (DT) such as serum calcitonin DT) are used as objective markers of progression [66].

Per ATA recommendations, loco-regional control via surgery, EBRT, radiofrequency ablation must be the mainstay in metastatic MTC whenever possible, such as in oligometastatic disease or single organ involvement [66,69,70]. Systemic therapy may be indicated for advanced progressive MTC with large tumor burden and progression in <1 year [71].

**The role of chemotherapy in MTC**

Cytotoxic chemotherapy has a limited role in the treatment of persistent or recurrent MTC due to the poor response rates (10%–15% partial response) and there is no data on survival benefit [72,73]. Combination chemotherapy based on dacarbazine, doxorubicin has been described in clinical trials, albeit with limited results [72,73]. Following the approval of TKIs, the revised ATA guidelines recommends chemotherapy as a last line, only after considering other systemic therapies.
The role of targeted therapies in MTC

Germline RET mutations are present in MEN2A and MEN2B. The identification of somatic RET mutations in sporadic MTC have led way to a preclinical and clinical trials to investigate the utility of targeted therapy [74,75]. Additionally, 18–80% of patient without somatic RET mutations have somatic RAS mutations [75]. VEGF receptors are also over expressed in MTC [76].

Multikinase inhibitors targeting RET and VEGFR2 showed promising results in phase II trials prompting phase III trials involving Vandetanib and Cabozantinib [77–79]. In 2011, the FDA approved these drugs for symptomatic or progressive MTC.

In the prospective, randomized, double-blind, phase III ZETA study, patients with unresectable, progressive metastatic MTC were randomized to vandetanib (300mg per day) or placebo. The results demonstrated a significant PFS prolongation of 11 months compared to placebo (HR: 0.46, p<0.0001) [80]. Partial responses were observed in 45% of patients treated with vandetanib, with a predicted median duration of response of 22 months [80]. The results were similar for patients with sporadic and hereditary MTC with and without RET mutations. However, a further subgroup analysis of PFS by M918T (RET) mutation positive showed higher response to vandetanib [81]. Notably, patients in the vandetanib arm also demonstrated improved quality of life and biochemical response. Adverse events (AEs) were mostly grade 1–2 with 35% requiring a dose reduction [81].

In a double-blind, phase III (EXAM) trial comparing cabozantinib with placebo, estimated median PFS was significantly higher with 11.2 months for cabozantinib versus 4.0 months for placebo (hazard ratio, 0.28; p<.001) [82]. Response rate was 28% with an estimated duration of response of 14.6 months [82]. Patients in the cabozantinib arm experienced a higher incidence of grade 3–4 AEs with discontinuation of drug in 16% of patients and a dose reduction in 79% of the patients [82,83]. The most frequent grade 3 or 4 AEs were diarrhea, palmar-plantar erythrodysesthesia, GI fistulas and fatigue [84]. In 2017, a final analysis of overall survival (OS) of the phase III EXAM trial was carried out. There was a 5.5-month numerical increase in median OS with cabozantinib versus placebo (26.6 versus 21.1 months) [85]. However, this difference did not reach statistical significance (stratified HR, 0.85; 95% CI, 0.64–1.12; P = 0.24) [85]. In exploratory analyses, the most significant OS benefit was observed in patients with RETM918T- positive mutation with 44.3 months [85].

Currently, there is no evidence-based guide for the initial selection of a TKI in the treatment of MTC. Until then, consideration should be given to underlying patient characteristics and past medical history with identification of factors that may predispose to certain adverse events [86]. (Table 2). For instance, Vandetanib is known to cause QT prolongation is therefore contraindicated in patients with a history of torsades de pointes and underlying cardiac pathology [87].

Future therapies in MTC

Other multikinase inhibitors, specifically those targeting RET and VEGF such as sunitinib, sorafenib and lenvatinib have shown benefit in phase II trials [88,89]. Combination
therapies, second line TKIs and other therapeutically targetable mutations in MTC are being investigated [90].

**Anaplastic thyroid cancer (ATC)**

Anaplastic thyroid cancer has an incidence of 1.7% with a mortality rate of 33%–50%. The median survival is 5 months with a high rate of recurrence [91]. ATC can result from dedifferentiation as result of multistep mutations or can arise de novo [92].

Given the aggressive nature of the disease, patients are regarded as Stage IV on diagnosis with Stage IVC defined by the presence of distant metastases [91]. Due to the dismal prognosis and poor response to standard therapies, the oncologist’s involvement tends to be upfront in the therapeutic management of ATC. The goals of therapy whether curative or palliative should be defined in advance [91,93]. The standardized treatment for curative intent ATC is a multimodal approach and involves timely surgery, external beam radiation with radiosensitizing chemotherapy [92]. The initial intent should be loco-regional control of the disease despite the presence of distant metastases. Stage IVC disease is seen in 1/3 of the patients with ATC [93]. It is reasonable to consider systemic therapy initially on presentation in these patients [93].

**The role of chemotherapy in ATC**

Doxorubicin, taxanes (paclitaxel or docetaxel) and platins (cisplatin or carboplatin) have demonstrated activity in ATC with response rates ranging from 15%–25% [93]. A US national cancer registry study showed longer median survival rates for stage IVA and IVB in patients who received chemotherapy in addition to surgery and radiation [94].

Apart from the previously defined role of radiosensitizing chemotherapy [95], a few studies have also demonstrated the utility of neoadjuvant chemotherapy in patients with stage IVA and IVB tumors allowing them to undergo successful resection [96–98]. A study by Kumar et al., explores the multimodality therapy for patients who desire and for whom aggressive treatment is feasible [99].

**Future therapies in ATC**

Over the last decade, the identification of the various genetic and molecular mutations which occur in ATC have led to several clinical trials to explore the efficacy of targeted therapy. However, no single agent has yet provided promising results with further preclinical and clinical studies underway. The most common mutation identified in ATC is TP53 tumor suppressor gene [100]. Two signaling pathways including PI3K/Akt/mTOR and RAF/MEK/ERK pathways also play a key role in dedifferentiation and tumor cell growth in ATC [101,102].

The 2012 ATA guidelines do not currently recommend routine molecular profiling however based on limited case reports and clinical trials, this information may be a critical guide for targeted therapies in the near future.

In separate clinical trials, fosbretabulin and crolibulin; tubular binding proteins which impair neovascularization of the tumors through mitotic arrest and cell death in endothelial cells,
were administered in combination with standardized chemotherapy; both produced disappointing results [103,104].

**Multikinase inhibitors:** Within the realm of MKIs, phase II trials involving sorafenib, sunitinib and pazopanib did not yield positive results [105–107]. Based on promising results from a Japanese phase II trial, lenvatinib is currently being investigated () [108]. Imatinib also appears to show activity in ATC however further validation is needed [109].

**Immune check point inhibitors:** A high expression of anti–programmed death 1/programmed death-ligand 1 (PDL1) was seen in ATC [110]. Two clinical trials investigating the role of Pembrolizumab () and Atezolizumab plus various targeted therapies based on genetic mutations () are currently underway.

In 2018, a phase II, open-label trial investigated Dabrafenib plus trametinib in patients with **BRAF**V600E mutations in ATC [111]. The overall response rate (the primary endpoint) was 69% [111]. Based on these findings, the FDA approved Dabrafenib plus trametinib for treatment of **BRAF** V600E- mutated ATC.

**Conclusion**

RAI refractory DTC responds poorly to conventional therapy due to the lack of RAI avidity leading to progressive disease. Therefore, the oncologist’s involvement is largely only in the treatment of RAI resistant tumors and as a last approach in metastatic DTC. Progressive metastatic disease in both RAI refractory DTC and metastatic MTC, especially single or oligometastatic disease, should be addressed whenever possible with loco regional control measures such as radiation, RFA or chemoembolization etc. In the setting of asymptomatic or indolent metastases, a watch and wait method is also recommended. The need for systemic therapy arises when disease progression leads to development of symptoms, increased tumor burden, encroachment on vital structures and when loco regional therapeutic options have failed or are limited. With the approval of targeted therapies, chemotherapy has an even less significant role in the systemic treatment of RAI-refractory DTC and metastatic MTC. Prior to the initiation of TKIs, patient comorbidities should be considered and an open discussion with the patient regarding the implications of therapy including adverse events and potential for a lower quality of life is needed. Failure of one TKI does not preclude from the use of second line agents. There are no new recommendations or advances in the treatment of ATC. Intent of treatment should be established. Treatment of ATC includes combination chemotherapy, surgery and radiation whenever possible. Additionally, thyroid cancers may occur due to NTRK fusion driven oncogenes. The approval of Larotrectinib provides yet another option for NTRK fusion thyroid cancer. Clinical trials further exploring the role of targeted therapies, radio iodine re-sensitization and immunotherapy are ongoing for thyroid cancer.

**Acknowledgement**

This work is supported, in part, by the efforts of Dr. Moro O. Salifu M.D., M.P.H., M.B.A., M.A.C.P., Professor and Chairman of Medicine through NIH Grant number S21MD012474.
References

1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26: 1–133. Link: [PubMed: 26462967]

2. Davies L, Welch HG (2014) Current Thyroid Cancer Trends in the United States. JAMA Otolaryngol Head Neck Surg 140: 317–322. Link: [PubMed: 24557566]

3. Cabanillas ME, Mcfadden DG, Durante C (2016) Thyroid cancer. Lancet 388: 2783–2795.

4. Mazzaferri E (2003) Management of Papillary and Follicular Thyroid Cancer. Endocrine Surgery.

5. Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY (1998) Use of Radioactive Iodine for Thyroid Remnant Ablation in Well-Differentiated Thyroid Carcinoma to Replace Thyroid Reoperation. Am J Clin Oncol 21: 77–81. Link: [PubMed: 9499265]

6. Gottlieb JA, Hill CS (1974) Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290: 193–197. Link: [PubMed: 4808917]

7. Pacini F (2012) Thyroid microcarcinoma. Best Practice and Research Clinical Endocrinology and Metabolism 26: 381–389.

8. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, et al. (1990) Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy. Tumori 76: 480–483. Link: [PubMed: 2256195]

9. Besic N, Auersperg M, Gazic B, Dremelj M, Zagar I (2012) Neoadjuvant Chemotherapy in 29 Patients with Locally Advanced Follicular or Hürthle Cell Thyroid Carcinoma: A Phase 2 Study. Thyroid 22: 131–137. Link: [PubMed: 22175241]

10. Besic N, Auersperg M, Dremelj M, Vidergar-Kralj B, Gazic B (2013) Neoadjuvant Chemotherapy in 16 Patients with Locally Advanced Papillary Thyroid Carcinoma. Thyroid 23: 178–184. Link: [PubMed: 22946465]

11. Dang RP, Mcfarland D, Le VH, Camille N, Miles BA, et al. (2016) Neoadjuvant Therapy in Differentiated Thyroid Cancer. Int J Surg Oncol 2016: 3743420 Link: [PubMed: 27747102]

12. Shimaoka K, Schoenfeld DA, Dewys WD, Creech RH, Deconti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56: 2155–2160. Link: [PubMed: 3902203]

13. Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, et al. (2008) Chemotherapy with Doxorubicin in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium. Horm Metab Res 40: 210–213. Link: [PubMed: 18348081]

14. Argiris A, Agarwala SS, Karamouzis MV, Burmeister LA, Carty SE (2007) A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Inves New Drugs 26:183–188. Link: [PubMed: 2050336]

15. Kim JH, Leeper RD (1987) Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60: 2372–2375. Link: [PubMed: 3664425]

16. Spano JP, Vano Y, Vignot S, De La Motte Rouge T, Hassani L, et al. (2011) GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Med Oncol 29: 1421–1428. Link: [PubMed: 21947747]

17. Sherman S (2010) Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma. Clin Oncol 22: 464–468. Link: [PubMed: 20528888]

18. Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, et al. (2014) Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2: 356–358. Link: [PubMed: 24795243]

19. Schlumberger M, Sherman SI (2011) ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 166: 5–11. Link: [PubMed: 21890651]
20. Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, et al. (2012) The Impact of Distant Metastases at Presentation on Prognosis in Patients Differentiated Carcinoma of the Thyroid Gland. Thyroid 22: 884–889. Link: http://bit.ly/2k0hctc [PubMed: 22827579]

21. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, et al. (2006) Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. J Clin Endocrinol Metab 91: 2892–2899. Link: http://bit.ly/2IFpCfd [PubMed: 16684830]

22. Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, et al. (2009) 124I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison. J Nucl Med 50: 1844–1847. Link: http://bit.ly/2m5NC6x [PubMed: 19837771]

23. Robbins RJ1, Wan Q, Grewal RK, Reibke R, Gonen M, et al. (2006) Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Scanning. J Clin Endocrinol Metab 91: 498–505. Link: http://bit.ly/2IIYQst [PubMed: 16303836]

24. Brose MS, Smit J, Capdevila J, Elisei R, Notting C, et al. (2012) Regional approaches to the management of patients with advanced, radioiodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther 12: 1137–1147. Link: http://bit.ly/2IBsN2y [PubMed: 23098114]

25. Eisenhauer EA, Therasse P, Bogarets J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228–247. Link: http://bit.ly/2kMMk77 [PubMed: 19097774]

26. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, et al. (2009) Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19: 451–457. Link: http://bit.ly/2kzujBT [PubMed: 19281429]

27. Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ (2013) Clinical, safety, and economic evidence in radioactive iodine–refractory differentiated thyroid cancer: a systematic literature review. Thyroid 23: 392–407. Link: http://bit.ly/2lZcTip [PubMed: 23294230]

28. Sacks W, Braunstein GD (2013) Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer. Endocr Pract 20: 263–275. Link: http://bit.ly/2lZcRqN

29. Gruber JJ, Colevas AD (2015) Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 20: 113–126. Link: http://bit.ly/2lHDO22 [PubMed: 25616432]

30. Raue F, Frank-Raue K (2016) Thyroid cancer: risk-stratified management and individualized therapy. Clin Cancer Res 22: 5012–5021. Link: http://bit.ly/2k4ZqoK [PubMed: 27742787]

31. Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13: 184–199. Link: http://bit.ly/2kx6nPf [PubMed: 23429735]

32. Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, et al. (2013) Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab 98: E829–E836. Link: http://bit.ly/2kn3lZg [PubMed: 23533233]

33. Vasko VV, Saji M (2007) Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr Opin Oncol 19: 11–17. Link: http://bit.ly/2ICMhUk [PubMed: 17133106]

34. Nikiforova MN, Nikiforov YE (2008) Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8: 83–95. Link: http://bit.ly/2kxaV8A [PubMed: 18088233]

35. Licitra L, Locati LD, Greco A, Granata R, Bossi P (2010) Multikinase inhibitors in thyroid cancer. Eur J Cancer 46: 1012–1018. Link: http://bit.ly/2m2tp9 [PubMed: 20171085]

36. Leboulleux S, Bastholt L, Krause T, De la Fouchardiere C, Tennvall J, et al. (2012) Vandetanib in locally advanced or metastatic differentiated thy-roid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13: 897–905. Link: http://bit.ly/2lJ9QL2 [PubMed: 22896787]

37. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, et al. (2008) Axitinib is an active treatment for all histologic subtypes of ad-vanced thyroid cancer: results from a phase II study. J Clin Oncol 26: 4708–4713. Link: http://bit.ly/2k80tV2 [PubMed: 18541897]
38. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, et al. (2010) Efficacy of pazopanib in progressive, radio iodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11: 962–972. Link: [PubMed: 20851682]

39. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, et al. (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384: 319–328. Link: [PubMed: 24768112]

40. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, et al. (2014) A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).

41. Schlumberger M, Jarzab B, Elisei R, Siena S, Bastholt L, et al. (2013) Phase III randomized, double-blinded, placebo-controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)-exploratory analyses of patient-reported outcomes. Thyroid 23: A49–A50.

42. Capdevila J, Iglesias L, Halperin I, Segura A, Martínez-Trufero J (2012) Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 19: 209–216. Link: [PubMed: 22285864]

43. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, et al. (2013) The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98: 31–42. Link: [PubMed: 23185034]

44. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, et al. (2017) Incidence and timing of common adverse events in Len-vatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 56:121–128. Link: [PubMed: 28155175]

45. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, et al. (2011) Analysis of the efficacy and toxicity of sorafenib in thyroid cancer a phase II study in a UK based population. Eur J Endocrinol 165: 315–322. Link: [PubMed: 21566072]

46. Thomas L, Lai SY, Dong W, Feng L, Dadu R, et al. (2014) Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 19: 251–258. Link: [PubMed: 24563075]

47. Bible KC, Ain KB, Rosenthal MS (2014) Protein kinase inhibitor therapy in advanced thyroid cancer: ethical challenges and potential solutions. Int J Endocrine Oncol 1: 145–151. Link: [PubMed: 21997074]

48. Colevas AD, Shah MH (2012) Evaluation of patients with disseminated or locoregionally advanced thyroid cancer: a primer for medical oncologists. In American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting 384–388.

49. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, et al. (2010) Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 7: 44–54. Link: [PubMed: 19997074]

50. Schlumberger M, Leboullieux S (2015) Treatment of distant metastases from follicu-lar cell-derived thyroid cancer. F1000prime rep 7: 22 Link: [PubMed: 25750740]

51. Farooki A, Leung V, Tala H, Tuttle RM (2012) Skeletal-related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab 97: 2433–2439. Link: [PubMed: 22564664]

52. Wertenbroek MW, Links TP, Prins TR, Plukker JT, Van der Jagt EJ, et al. (2008) Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Thyroid 18: 1105–1110. Link: [PubMed: 18816179]

53. Tumino D, Frasca F, Newbold K (2017) Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer. Front Endocrinol 8: 312 Link: [PubMed: 24686464]
55. Worden F (2014) Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol 6: 267–279. Link: http://bit.ly/2kJdN [PubMed: 25364392]

56. Viola D, Valerio L, Molinero A, Agate L, Bottici V, et al. (2016) Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocrine relat cancer 23: R185–R205. Link: http://bit.ly/2k3YAH

57. Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, et al. (2008) Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer drugs 19: 547–552. Link: http://bit.ly/2BJKda [PubMed: 18412222]

58. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, et al. (2014) Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first line sorafenib. J Clin Endocrinol Metab 99: 2086–2094. Link: http://bit.ly/2k89Ok [PubMed: 24628550]

59. Massirotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, et al. (2014) Tyrosine kinase inhibitor treatments in pa-tients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 170: 575–582. Link: http://bit.ly/2m4YoI [PubMed: 24424318]

60. Cabanillas ME, Brose MS, Ramies DA, Lee Y, Miles D, et al. (2012) Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). J Clin Oncol 30: 5547–5547. Link: http://bit.ly/2I0FcT

61. Naoon GE, Morkos M, Kim B, Arafat W (2018) Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol Cancer 17: 51 Link: http://bit.ly/2kx9Us [PubMed: 29455653]

62. Venkataaraman GM, Yatin M, Marcinek R, Ain KB (1999) Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na”/I” symporter gene methylation status. J Clin Endocrin Metabolism 84: 2449–2457. Link: http://bit.ly/2kwiO1

63. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, et al. (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. Eng J Med 368: 623–632. Link: http://bit.ly/2mpcse

64. Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ (2013) Redifferentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: A pilot study. J Clin Oncol 31: 6025 Link: http://bit.ly/2k81qN6

65. Doss-McFadden DG, Palmer EL, Daniels GH, Wirth LJ (2013) Redifferentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: A pilot study. J Clin Oncol 31: 6025 Link: http://bit.ly/2k81qN6

66. Higgins MJ, Forastiere A, Marur S (2009) New Directions in the Systemic Treatment of Metastatic Thyroid Cancer. Thyroid 23: 768–775. Link: http://bit.ly/2kzyZs

67. Klooos RT, Eng C, Evans DB, Francis GL, Gagel RF, et al. (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19: 565–612. Link: http://bit.ly/2IAYQ9 [PubMed: 19469690]

68. Weber T, Schilling T, Raue KF, Benkmann MC, Hinz U, et al. (2001) Impact of modified radical neck dissection on biochemical cure in me-dullary thyroid carcinomas. Surgery 130: 1044–1049. Link: http://bit.ly/2s5HmM5 [PubMed: 11742336]

69. Hadoux J, Pacini F, Tuttle RM, Schlumberger M (2016) Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol 4: 64–71. Link: http://bit.ly/2lZ6nX [PubMed: 26608066]

70. Cappagli V, Bottici V, Elisei R (2016) Clinical management of a patient with a locally recurrent medullary thyroid cancer and asymptomatic slowly progressing distant metastases. Thyroid Cancer 347–354. Link: http://bit.ly/2kyhKK

71. Leboullueux S, Baudin E, Travagli JP, Schluumberger M (2004) Medullary thyroid carcinoma. Clin Endocrinol 61: 299–310. Link: http://bit.ly/2kkGnXP

72. Cabanillas ME, Hu MI, Jimenez C (2014) Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat and with which drug those are the questions. J Clin Endocrinol Metab 99: 4390–4396. Link: http://bit.ly/2lJj3 [PubMed: 25238206]

73. Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, et al. (1994) Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5: 763–765. Link: http://bit.ly/2s5Q0B [PubMed: 7826911]

74. Petursson SR (1988) Metastatic medullary thyroid carcinoma: Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 62: 1899–1903. Link: http://bit.ly/2k9efXw [PubMed: 3167804]
74. Roskoski R, Nejad AS (2017) Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacol Res 128: 1–17. Link: http://bit.ly/2kwZ5vh [PubMed: 29284153]

75. Drilon A, Hu ZI, Lai GGY, Tan DSW. (2018) Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 15: 151–167. Link: http://bit.ly/2k9eaDc [PubMed: 29134959]

76. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, et al. (2010) Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20: 863–871. Link: http://bit.ly/2lzMQgD [PubMed: 20615131]

77. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, et al. (2009) Phase II study of safety and efficacy of motesanib in pa-tients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27: 3794–3801. Link: http://bit.ly/2m3Mtw7 [PubMed: 19564535]

78. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, et al. (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26: 4708–4713. Link: http://bit.ly/2k80tV2 [PubMed: 18541897]

79. Wells SA, Gosnell JE, Gagel RF, Moley JF, Pfister D, et al. (2010) Vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28: 767–772. Link: http://bit.ly/2lIXXHD [PubMed: 20065189]

80. Wells SA Jr, Robinson BG, Gelg RF, Drale H, Fagin JA, et al. (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30: 134–141. Link: http://bit.ly/2lAXJjt [PubMed: 22025146]

81. Maia AL, Wajner SM, Vargas CV (2017) Advances and controversies in the management of medullary thyroid carcinoma. Curr Opin Oncol 29: 25–32. Link: http://bit.ly/2m3LH2b [PubMed: 27792051]

82. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, et al. (2013) Cabozantinib in progressive medullary thyroid cancer. J Clinical Oncol 31: 3639–3646. Link: http://bit.ly/2kwYOj [PubMed: 24002501]

83. Sherman SJ, Cohen EE, Schoffski P, Elisei R, Schlumberger M, et al. (2013) Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study. J Clin Oncol 31 Link: http://bit.ly/2k8UBA

84. Weitzman SP, Cabanillas ME (2015) The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res 7: 265–278. Link: http://bit.ly/2ICG6sC [PubMed: 26316818]

85. Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, et al. (2017) Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol 28: 2813–2819. Link: http://bit.ly/2k807ha [PubMed: 29045520]

86. Cabanillas ME, Hu MI, Jimenez C (2014) Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat and with which drug those are the questions. J Clin Endocrinol Metab 99: 4390–4396. Link: http://bit.ly/2LIjy3 [PubMed: 25238206]

87. Brose MS, Bible KC, Chow LQM, Gilbert J, Grande C, et al. (2018) Management of treatment related toxicities in advanced medullary thyroid cancer. Cancer Treat Rev 66: 64–73. Link: http://bit.ly/2kzwJjU [PubMed: 29704768]

88. Stjepanovic N, Capdevila J (2014) Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics 8: 129–139. Link: http://bit.ly/2knm1xb [PubMed: 24748771]

89. Sherman SJ, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, et al. (2016) Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer 122: 3856–3864. Link: http://bit.ly/2kyp3P4 [PubMed: 27525386]

90. Priya SR, Dravid CS, Digumarti R, Dandekar M (2017) Targeted Therapy for Medullary Thyroid Cancer: A Review. Front Oncol 7: 238 Link: http://bit.ly/2k9cABg [PubMed: 29057215]

91. Ranganath R, Shah MA, Shah AR (2015) Anaplastic thyroid cancer. Curr Opin Endocrinol Diabetes Obes 22: 387–391. Link: http://bit.ly/2lAWuRI [PubMed: 26313900]
92. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, et al. (2012) American Thyroid Association guidelines for management of pa-tients with anaplastic thyroid cancer. Thyroid 22: 1104–1139. Link: [PubMed: 23130564]

93. Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R (2016) Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy. J oncol practice 12: 511–518. Link: [PubMed: 25713779]

94. Keutgen XM, Sadowski SM, Kebebew E (2015) Management of anaplastic thyroid cancer. Gland surg 4: 44–51. Link: [PubMed: 23839797]

95. Haymart MR, Banerjee M, Yin H, Worden F, Griggs JJ (2013) Marginal treatment benefit in anaplastic thyroid cancer. Cancer 119: 3133–3139. Link: [PubMed: 23839797]

96. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, et al. (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86: 1848–1853. Link: [PubMed: 12085174]

97. Busnardo B, Daniele O, Pelizzo MR, Mazzarotto R, Nacamulli D, et al. (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Invest 23: 755–761. Link: [PubMed: 11194710]

98. Uruno T, Ogimi Y, Saito F, Masaki C, Akaishi J, et al. (2015) Proposal of a new staging system and treatment algorithm for anaplastic thyroid cancer by induction weekly paclitaxel. Thyroid 25.

99. Kumar A, Prasongsook N, Kasperbauer J (2015) Outcomes in response to aggressive multi modal therapy in anaplastic thyroid cancer: the mayo clinic experience. Thyroid 25.

100. Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, et al. (2015) Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 24: 2318–2329. Link: [PubMed: 25576899]

101. Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cance 16: 17–44. Link: [PubMed: 28282720]

102. Samimi H, Fallah P, Naderi Sohi A, Tavakoli R, Naderi M, et al. (2017) Precision medicine approach to anaplastic thyroid cancer: advances in targeted drug therapy based on specific signaling pathways. Acta Med Iran 55: 200–208. Link: [PubMed: 25396774]

103. Granata R, Locati LD, Licitra L (2014) Fosbretabulin for the treatment of anaplastic thyroid cancer. Future Oncol 10: 2015–2021. Link: [PubMed: 25396774]

104. Granma AW, Balasubramaniam S, Fojo AT, Ward J, Wells SA (2013) Phase I/II trial of crolibulin and cisplatin in solid tumors with a focus on anaplastic thyroid cancer: Phase I results. J Clin Oncol. Link: [PubMed: 28662274]

105. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ (2014) A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 99: 1687–1693. Link: [PubMed: 24606083]

106. Ravaud S, Kiyota N, Yamazaki T, Chayahara N, Nakano K (2016) Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results. J Clin Oncol 34: 6088–6088. Link: [PubMed: 20718683]

107. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, et al. (2010) A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20: 975–980. Link: [PubMed: 20718683]

108. Dadu R, Canales JR, Wistuba I, Tian W, Lui H, et al. (2015) Targeting immune system in anaplastic thyroid cancer (ATC): a potential treatment approach. Thyroid 25: 749.
111. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, et al. (2018) Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 36: 7–13. Link: http://bit.ly/2kx0hyE [PubMed: 29072975]
Table 1:
Common molecular mutations found in thyroid cancer [29–34,75,76,100–102].

| Type                      | Common Molecular Mutations |
|---------------------------|-----------------------------|
| Follicular                | RAS (HRAS, NRAS, KRAS), PIK3CA/B, EGFR, PAX8-PPAR-γ, VEGFR, TERT promoter, IDH1 |
| Papillary                 | BRAF V600E, RET (RETPTC1, RETPTC3), RAS PIK3CA/B, EGFR, PAX8-PPAR-γ, VEGFR, TERT promoter, IDH1 |
| Medullary (Hereditary)    | RET (40%–60%), RAS (KRAS, HRAS, NRAS), MET, VEGF2, 3, FGFR |
| Medullary (Sporadic)      | Tp53, PTEN, RAS, RET/PTC-1, BRAF, PAX8-PPAR-γ, PIK3CA, ALK, AKT |
| Anaplastic                | Tp53, PTEN, RAS, RET/PTC-1, BRAF, PAX8-PPAR-γ, PIK3CA, ALK, AKT |
Table 2:
Showing common side effects, serious adverse events and laboratory abnormalities associated with FDA approved targeted multi kinase inhibitors [40–45,80–82,89].

| Sorafenib | Lenvatinib |
|-----------|------------|
| **Common adverse effects** | **Common adverse effects** |
| Hand-foot skin reaction | Hypertension |
| Diarrhea | Diarrhea |
| Alopecia | Fatigue/Anorexia/Weight loss |
| Rash or desquamation | Nausea |
| Fatigue/anorexia/weight loss | Stomatitis |
| Hypertension | Palmar-plantar erythrodysesthesia |
| Oral mucositis | |
| **Serious/noteworthy side effects** | **Serious/noteworthy side effects** |
| Secondary malignancy (squamous cell carcinoma, acute myeloid leukemia, bladder cancer) | Arterial thromboembolic events |
| Dyspnea | Venous thromboembolic effects |
| Pleural effusion | Renal failure |
| **Common Laboratory abnormalities** | **Common Laboratory abnormalities** |
| Serum thyroid stimulation hormone (TSH) increase | Increased serum thyrotropin levels |
| Hypocalcemia | |
| Increased ALT, AST | |
| **Vandetanib** | **Cabozantinib** |
| **Common adverse effects** | **Common adverse effects** |
| Diarrhea | Diarrhea |
| Rash | Palmar plantar erythrodysesthesia |
| Nausea | Weight loss/Anorexia |
| Hypertension | Nausea |
| Headache | Fatigue |
| Fatigue/Anorexia | Dysgeusia |
| Acne | Hypertension |
| **Serious/noteworthy side effects** | **Serious/noteworthy side effects** |
| Diarrhea | Diarrhea |
| Hypertension | Fatigue |
| QTc prolongation (black box warning) | Hypertension |
| Palmar plantar erythrodysesthesia | Fistula, perforations (black box warning) |
| Dysgeusia | Hemorrhage |
| Hemorrhage | Weight loss/Anorexia |
| Common Laboratory abnormalities | Common Laboratory abnormalities |
|--------------------------------|--------------------------------|
| Hypocalcemia                  | Increased AST, ALT             |
| Increased ALT                 | Increased alkaline phosphatase |
| Hypoglycemia                  | Hypocalcemia                   |